Akademik Veri Yönetim Sistemi
Metabolic Brain Disease, cilt.40, sa.8, 2025 (SCI-Expanded)
Alzheimer’s disease (AD) is the most common cause of dementia. The disease spreads over the world and has an impact on human health and welfare. The patients suffer from cognitiv disability in addition to economic and social effects. It is urgently necessary to find effective medication for cognitive decline because it appears to be a central focus of neurological and neurodegenerative illnesses. Cognitive decline is an intriguing pathophysiological state. Such underlying causes of cognitive impairment linked to neurodegeneration include oxidative damage and diminished cholinergic neurotransmission. The approved therapies for neurodegenerative diseases like AD are known to have undesirable side effects and merely offer symptomatic alleviation. Honeybee products have long been recognized for their therapeutic and health-improving properties. The antioxidant and anti-inflammatory activities of bee products and their ingredients are promising agents for AD. The current review aimed to collect and expose the different studies conducted on the neuroprotective potential of honeybee products such as bee venom and propolis or their active components chrysin, ferulic acid, and quercetin in combination with the conventional anti-AD or anti-dementia treatments such as donepezil and rivastigmine. Additionally, the active component chitosan was found to form effective nanoparticles in treating the neurodegenerative diseases in concern. Although the studies collected on this topic were few, they highlighted the potential synergistic effect of honeybee products in treating AD. In conclusion, bee products combined with donepezil and rivastigmine can be considered a potential neuroprotective agent against AD. Further studies are needed to support the preclinical studies and promote the clinical trials.